Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes

Background:The majority of patients diagnosed with advanced epithelial ovarian carcinoma (EOC) relapse with resistant disease, and there are no biomarkers that possess clinical utility to identify or monitor these patients. This study aimed to identify secreted proteins (‘secretome’) collected from human EOC cell lines that differ in their inherent platinum sensitivity.Methods:Secreted proteins collected from conditioned medium from ovarian cancer cell lines that vary in their sensitivity to cisplatin were digested with trypsin and analysed by liquid chromatography-tandem mass spectrometry for peptide identification.Results:Of the 1688 proteins identified, 16 possessed significant differential abundances (P<0.05) between the platinum-resistant and -sensitive cell lines. A number of these were verified by immunoblot, including COL11A1, which was also found to be associated with worse progression-free survival (PFS; N=723) and overall survival (OS; N=1183) as assessed from publicly available transcript expression data from ovarian cancer tumour specimens.Conclusion:Secretome proteomics of EOC cells resulted in the identification of a novel candidate biomarker, COL11A1. The expression level of COL11A1 correlates to worse PFS and OS, and is predicted to reside in peripheral circulation making this an attractive candidate for validation in sera as a biomarker of cisplatin resistance and poor outcome.

[1]  Jian-Hua Fu,et al.  Comparative proteomic analysis of the esophageal squamous carcinoma cell line EC109 and its multi-drug resistant subline EC109/CDDP. , 2009, International journal of oncology.

[2]  A. van Dalen,et al.  Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin‐2 receptor α levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma , 2002, Cancer.

[3]  Gregory Stephanopoulos,et al.  Amplification of phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis , 2012, BMC Proceedings.

[4]  R. Dhir,et al.  Assessment of buffer systems for harvesting proteins from tissue interstitial fluid for proteomic analysis. , 2010, Journal of Proteome Research.

[5]  E. Diamandis,et al.  Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer. , 2009, Journal of proteome research.

[6]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[7]  A. Sytkowski,et al.  Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780. , 2011, Cancer letters.

[8]  D. Zurakowski,et al.  Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels. , 2011, Gynecologic oncology.

[9]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[10]  Yong Zhang,et al.  SPD—a web-based secreted protein database , 2004, Nucleic Acids Res..

[11]  B. Seliger,et al.  Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell carcinoma , 2009, Journal of Translational Medicine.

[12]  R. Grafström,et al.  Matrix metalloproteinase-7 and -13 expression associate to cisplatin resistance in head and neck cancer cell lines. , 2009, Oral Oncology.

[13]  L. Galluzzi,et al.  Molecular mechanisms of cisplatin resistance , 2012, Oncogene.

[14]  Long‐juan Zhang,et al.  Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1 , 2012, Journal of Neuro-Oncology.

[15]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[16]  I. Gromova,et al.  Identification of Extracellular and Intracellular Signaling Components of the Mammary Adipose Tissue and Its Interstitial Fluid in High Risk Breast Cancer Patients , 2005, Molecular & Cellular Proteomics.

[17]  Emilio Marengo,et al.  The principle of exhaustiveness versus the principle of parsimony: a new approach for the identification of biomarkers from proteomic spot volume datasets based on principal component analysis , 2010, Analytical and bioanalytical chemistry.

[18]  Jun Yu,et al.  Epigenetic identification of ubiquitin carboxyl‐terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors , 2008, Hepatology.

[19]  Laurent Ozbun,et al.  A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. , 2008, Cancer research.

[20]  N. Futran,et al.  Tumor and Salivary Matrix Metalloproteinase Levels Are Strong Diagnostic Markers of Oral Squamous Cell Carcinoma , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[21]  S. Hanash,et al.  Mining the plasma proteome for cancer biomarkers , 2008, Nature.

[22]  T. Putti,et al.  The Ubiquitin Peptidase UCHL1 Induces G0/G1 Cell Cycle Arrest and Apoptosis Through Stabilizing p53 and Is Frequently Silenced in Breast Cancer , 2012, PloS one.

[23]  P Maisonneuve,et al.  Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. , 2006, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[24]  M. Walsh,et al.  Matrix Metalloproteinase-10 Promotes Kras-Mediated Bronchio-Alveolar Stem Cell Expansion and Lung Cancer Formation , 2011, PloS one.

[25]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[26]  R. Dhir,et al.  Differential proteomic analysis of renal cell carcinoma tissue interstitial fluid. , 2011, Journal of proteome research.

[27]  B. Bauvois,et al.  New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. , 2012, Biochimica et biophysica acta.

[28]  W. Weichert,et al.  A prognostic gene expression index in ovarian cancer—validation across different independent data sets , 2009, The Journal of pathology.

[29]  C A SALVATORE,et al.  [Carcinoma of the ovary]. , 1960, Anais brasileiros de ginecologia.

[30]  D. Bonatto,et al.  Importance of the trans-sulfuration pathway in cancer prevention and promotion , 2007, Molecular and Cellular Biochemistry.

[31]  Anil Potti,et al.  An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  T. Conrads,et al.  Proteomic Analysis of Ovarian Cancer Proximal Fluids: Validation of Elevated Peroxiredoxin 1 in Patient Peripheral Circulation , 2011, PloS one.

[33]  E. Diamandis,et al.  Mining the Ovarian Cancer Ascites Proteome for Potential Ovarian Cancer Biomarkers*S , 2009, Molecular & Cellular Proteomics.

[34]  Benjamin Haibe-Kains,et al.  curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome , 2013, Database J. Biol. Databases Curation.

[35]  Darryl B. Hardie,et al.  Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). , 2004, Journal of proteome research.

[36]  A. Ignatchenko,et al.  A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. , 2008, Journal of proteome research.

[37]  S. Hanash,et al.  Proteomic Analysis of Ovarian Cancer Cells Reveals Dynamic Processes of Protein Secretion and Shedding of Extra-Cellular Domains , 2008, PloS one.

[38]  S. Qiu,et al.  Sp1 is involved in regulation of cystathionine γ-lyase gene expression and biological function by PI3K/Akt pathway in human hepatocellular carcinoma cell lines. , 2012, Cellular signalling.

[39]  T. Ushijima,et al.  Silencing of the UCHL1 gene in human colorectal and ovarian cancers , 2006, International journal of cancer.

[40]  J. Watkinson,et al.  Multi-cancer computational analysis reveals invasion-associated variant of desmoplastic reaction involving INHBA, THBS2 and COL11A1 , 2010, BMC Medical Genomics.

[41]  G. Azabdaftari,et al.  Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer , 2008, Molecular Cancer Therapeutics.

[42]  Á. Chamorro,et al.  Activation of Matrix Metalloproteinase‐3 and Agrin Cleavage in Cerebral Ischemia/Reperfusion , 2004, Journal of neuropathology and experimental neurology.

[43]  W. Wong,et al.  A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. , 2009, Cancer cell.

[44]  R. Aebersold,et al.  A High-Confidence Human Plasma Proteome Reference Set with Estimated Concentrations in PeptideAtlas* , 2011, Molecular & Cellular Proteomics.

[45]  M. Walsh,et al.  Matrix Metalloproteinase-10 Is Required for Lung Cancer Stem Cell Maintenance, Tumor Initiation and Metastatic Potential , 2012, PloS one.

[46]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.